HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study

Value of serum human epididymis secretory protein 4 as a marker for differential diagnosis of malignant and benign gynecological diseases of patients in southern China

“…However, HE4 display different results from those obtained by Moore et al whose positive rate was 12%, and by Ortiz-Munoz et al 12.6% in benign diseases [21]. Supplementary Table 1 summarized the recently studies of HE4, CA125, and ROMA for differentiating ovarian cancer from benign disease [14,[23][24][25][26][27][28][29][30][31]. However, these studies are not consistent with each other.…”

“…For ovarian cancer, ROMA demonstrated similar sensitivity and NPV to CA125, but higher specificity and PPV (specificity and PPV for ROMA compared to CA125, 80.6% vs. 70.2%, 54.1% vs. 43.6%, respectively). Many studies showed that ROMA algorithm displayed the best-balanced diagnostic performance to differentiate ovarian cancer from benign pelvic masses in the triage of patients to appropriate cancer centers for treatment by specialized gynecologic oncologists [14,[23][24][25][26][27][28][29][30][31] (Supplementary Table 1). However, these studies are not consistent with each other, may be caused by the different geographical origins, the different numbers of subjects investigated and the different measured systems used.…”

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

“…74,75 The FDA has approved the use of HE4 and CA 125 for estimating the risk for ovarian cancer in women with a pelvic mass, however, the NCCN Panel does not currently recommend the use of these biomarkers for determining the status of an undiagnosed pelvic mass. [76][77][78][79] Although no direct evidence exists that chest radiography or CT is necessary, panel members felt that it should be part of the overall evaluation of a patient before surgical staging if clinically indicated.…”

MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer

“…As there are no early specific symptoms, OC is diagnosed in advanced clinical stages in more than 70% cases when, despite appropriate treatment, 5-year survival rate drops to 30% [2]. Early diagnosis improves treatment outcomes and also dramatically reduces mortality rate [3]. However, adequate diagnostic methods are lacking and therefore novel technologies that would allow early detection of OC are urgently needed.…”